


1 1. (Original) Compounds having the structure of Formula 1:



5 **Formula I**

6 and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters,
7 enantiomers, diastereomers, N-oxides, polymorphs, prodrugs or metabolites, wherein

8 **T** is a five to seven membered heterocyclic ring, substituted heterocyclic ring, aryl or
9 substituted aryl, bound to the ring **C** with a linker **W**, and further substituted by a group
10 represented by **R**, wherein **R** is H, C₁₋₆ alkyl, F, Cl, Br, I, -CN, COR₅, COOR₅, N(R₆,R₇),
11 NHCO(R₈, R₉, R₁₀), CON(R₆, R₇), CH₂NO₂, NO₂, CH₂R₈, CHR₉, -CH = N-OR₁₀, -
12 C=CH-R₅, OR₅, SR₅, -C(R₉)=C(R₉)NO₂, C₁₋₁₂ alkyl substituted with one or more of F, Cl,
13 Br, I, OR₄, SR₄, wherein R₄ is hydrogen, alkoxy, aryl, heteroaryl, amines, substituted
14 amines, alkene substituted with aryl, heteroaryl or halogen; R₅ is H, C₁₋₁₂ alkyl, C₃₋₁₂
15 cycloalkyl, C₁₋₆ alkoxy, aryl, heteroaryl or C₁₋₆ alkyl substituted with one or more of F,
16 Cl, Br, I or OH;

17 R₆ and R₇ are independently H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆
18 alkoxy;


19 R₈ and R₉ are independently H, C₁₋₆ alkyl, F, Cl, Br, I, C₁₋₁₂ alkyl substituted with one or
20 more of F, Cl, Br, I, OR₅, SR₄, or N(R₆,R₇);

21 R₁₀= H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, aryl or
22 heteroaryl;

23 **n** is an integer in the range from 0 to 3;

- 24 X is H, CH, CH-S, CH-O, N, CHNR₁₁ or CCH₂NR₁₁, wherein R₁₁ is hydrogen, optionally
 25 substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkylcarbonyl, C₁₋₆
 26 alkylcarboxy, aryl or heteroaryl;
- 27 Y and Z are independently hydrogen, C₁₋₆ alkyl, C₃₋₁₂ cycloalkyl, C₀₋₃ bridging groups;
- 28 U and V are independently hydrogen, optionally substituted C₁₋₆ alkyl, F, Cl, Br, I, C₁₋₁₂
 29 alkyl substituted with one or more of F, Cl, Br, I;
- 30 W is CH₂, CO, CH₂NH, -NHCH₂, -CH₂NHCH₂, -CH₂-N (R₁₁)CH₂-, CH₂(R₁₁)N-,
 31 CH(R₁₁), S, CH₂(CO), NH, O, NR₁₁, (CO)CH₂, N(R₁₁)CON(R₁₁), N(R₁₁)C(=S)N(R₁₁),
 32 SO₂ or SO, wherein R₁₁ is hydrogen, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl,
 33 C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkylcarbonyl, C₁₋₆ alkylcarboxy, aryl or heteroaryl; and
- 34 R₁ is NHC(=O)R₂, NHC(=S)R₂, N(R₃, R₄), NR₃ or OR₃, wherein R₂, R₃, R₄ are
 35 independently hydrogen, thiocarbonyl, amines, substituted amines, aryl heteroaroyl,
 36 heterocyclic, aralkyl, aralkenyl, wherein the heteroaryl and heterocyclic rings may contain
 37 one or more heteroatoms selected from O, S and N; the aryl, heteroaryl, aralkyl and
 38 aralkenyl rings may be unsubstituted or substituted with one or more of alkyl, halogen,
 39 nitro, amino or methylenedioxy.

1 2. (Original) Compounds having the structure of Formula II:




5 **Formula II**


- 6 and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters,
 7 enantiomers, diastereomers, N-oxides, polymorphs, prodrugs or metabolites, wherein
- 8 R₁ is NHC(=O)R₂, NHC(=S)R₂, N(R₃, R₄), NR₃ or OR₃, wherein R₂, R₃, R₄ are
 9 independently hydrogen, thiocarbonyl, amines, substituted amines, aryl heteroaroyl,
 10 heterocyclic, aralkyl, aralkenyl, wherein the heteroaryl and heterocyclic rings may contain

- 11 one or more heteroatoms selected from O, S and N; the aryl, heteroaryl, aralkyl and
 12 aralkenyl rings may be unsubstituted or substituted with one or more of alkyl, halogen,
 13 nitro, amino or methylenedioxy;
- 14 U and V are independently hydrogen, optionally substituted C₁₋₆ alkyl, F, Cl, Br, I, C₁₋₁₂
 15 alkyl substituted with one or more of F, Cl, Br, I;
- 16 Y and Z are independently hydrogen, C₁₋₆ alkyl, C₃₋₁₂ cycloalkyl, C₀₋₃ bridging group;
- 17 X is H, CH, CH-S, CH-O, N, CHNR₁₁ or CCH₂NR₁₁, wherein R₁₁ is hydrogen, optionally
 18 substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl carbonyl, C₁₋₆
 19 alkylcarboxy, aryl or heteroaryl;
- 20 W is CH₂, C=O, CH₂NH, NHCH₂, CH₂NHCH₂, CH₂N(R₁₁)CH₂, CH₂N(R₁₁), CH(R₁₁),
 21 S, CH₂(C=O), NH, O, (CO)CH₂, N(R₁₁)CON(R₁₁), SO₂, SO, NR₁₁, N(R₁₁)C(=S)N(R₁₁);
 22 wherein R₁₁ is hydrogen, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy,
 23 C₁₋₆ alkyl carbonyl, C₁₋₆ alkylcarboxy, aryl or heteroaryl;
- 24 n is an integer in the range from 0 to 3;
- 25 Q₁ is O, S or NR₁₁, wherein R₁₁ is as defined above;
- 26 G, J, L are independently H, C₁₋₆ alkyl, F, Cl, Br, I, -CN, COR₅, COOR₅, N(R₆,R₇),
 27 NHCOC(R₈, R₉, R₁₀), CON(R₆, R₇), CH₂NO₂, NO₂, CH₂R₈, CHR₉, -CH = N-OR₁₀, -
 28 C=CH-R₅, OR₅, SR₅, -C(R₉)=C(R₉)NO₂, C₁₋₁₂ alkyl substituted with one or more of F, Cl,
 29 Br, I, OR₄, SR₄, wherein R₄ is as defined above; R₅ is H, C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆
 30 alkoxy, aryl or heteroaryl; C₁₋₆ alkyl substituted with one or more of F, Cl, Br, I or OH;
- 31 R₆ and R₇ are independently H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl or C₁₋₆
 32 alkoxy;
- 33 R₈ and R₉ are independently H, C₁₋₆ alkyl, F, Cl, Br, I, C₁₋₁₂ alkyl substituted with one or
 34 more of F, Cl, Br, I, OR₅, SR₄, N(R₆,R₇); and
- 35 R₁₀= H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, aryl or
 36 heteroaryl.


- 1 3. (Original) The compound according to claim 2 wherein in Formula II, ring C
 2 is 6-8 membered in size and the ring may have either two or three carbon atoms between
 3 each nitrogen atom comprising of:




- 6 and the ring C may be bridged to form a bicyclic system as shown below:




- 1 4. (Original) The compound according to claim 2 wherein in Formula II, ring C
 2 is substituted at positions Y and Z with alkyl groups, cycloalkyl groups, fluoro group,
 3 carboxylic and corresponding esters, amides, substituted alkyls or bridging alkyl groups as
 4 shown below:



- 2 5. (Original) The compound according to claim 2 wherein in Formula II, ring C
 3 is 6 membered in size and X is $-\text{CH}-(\text{NHR}_{11})$, or $>\text{CCH}_2\text{NHR}_{11}$ -, the ring C is selected
 4 from the group consisting of the following rings wherein R_{11} is the same as defined
 5 earlier,




10 or in addition to the above, the ring C includes the following structures:



1 6. (Original) The compound according to claim 2 having the structure of


2 Formula III:



Formula III

7 wherein U, V, Y, Z, X, W, G, J, L, R₁, R₁₁ and n are as defined earlier.


- 1 7. (Original) The compound according to claim 2 having the structure of
2 Formula IV:



6 **Formula IV**

7 wherein U, V, Y, Z, X, W, G, J, L, R₁ and n are as defined earlier.

- 1 8. (Original) The compound according to claim 2 having the structure of
2 Formula V:



6 **Formula V**

7 wherein U, V, X, Y, Z, W, G, J, L, R₁ and n are as defined earlier.

- 1 9. (Original) A compound selected from the group consisting of :

2 (S)-N-[[3-[3-Fluoro-4-[N-1-[4-{2-furyl-(5-nitro)methyl}] piperazinyl] phenyl]-2-
3 oxo-5-oxazolidinyl]methyl]-3-(2,4-dichlorophenyl)acrylamide (Compound No. 1)

4 (S)-N-[[3-[3-Fluoro-4-[N-1-[4-{2-furyl-(5-nitro)methyl}] piperazinyl] phenyl]-2-
5 oxo-5-oxazolidinyl]methyl]-3-(4-fluorophenyl)acrylamide (Compound No. 2)

6 (S)-N-[[3-[3-Fluoro-4-[N-1-[4-{2-furyl-(5-nitro)methyl}] piperazinyl] phenyl]-2-
7 oxo-5-oxazolidinyl]methyl]-2-benzo(b)furanamide (Compound No. 3)

8 (S)-N-[3-[3-Fluoro-4-[N-1-[4-{2-furyl-(5-nitro)methyl}] piperazinyl] phenyl]-2-
9 oxo-5-oxazolidinyl]methylamine (Compound No. 4)

- 10 (S)-N-[[3-[3-Fluoro-4-[N-1-[4-{2-furyl-(5-nitro)methyl}] piperazinyl] phenyl]-2-
11 oxo-5-oxazolidinyl]methyl]-3-(phenyl)acrylamide (Compound No. 5)
- 12 (S)-N-[[3-[3-Fluoro-4-[N-1-[4-{2-furyl-(5-nitro)methyl}] piperazinyl] phenyl]-2-
13 oxo-5-oxazolidinyl]methyl]-3-(1,3-benzodioxol-5-yl)acrylamide (Compound No.
14 6)
- 15 (S)-N-[[3-[3-Fluoro-4-[N-1-[4-{2-thienyl-(5-nitro)methyl}] piperazinyl] phenyl]-
16 2-oxo-5-oxazolidinyl]methyl]-3-(4-fluorophenyl)acrylamide (Compound No. 7)
- 17 (S)-N-[[3-[3-Fluoro-4-[N-1-[4-{2-thienyl-(5-nitro)methyl}] piperazinyl] phenyl]-
18 2-oxo-5-oxazolidinyl]methyl]-3-(4-nitrophenyl)acrylamide (Compound No. 8)
- 19 (S)-N-[[3-[3-Fluoro-4-[N-1-[4-{2-thienyl-(5-nitro)methyl}] piperazinyl] phenyl]-
20 2-oxo-5-oxazolidinyl]methyl]-3-(2,4-dichlorophenyl)acrylamide (Compound
21 No.9)
- 22 (S)-N-[1-[[3-[3-Fluoro-4-[N-1-[4-{2-furyl-(5-nitro)methyl}] piperazinyl] phenyl]-
23 2-oxo-5-oxazolidinyl]methyl]]-thiourea (Compound No. 10)
- 24 (S)-N-[[3-[3-Fluoro-4-[N-1-[4-{2-thienyl-(5-nitro)methyl}]piperazinyl]phenyl]-2-
25 oxo-5-oxazolidinyl]methyl]isothiocyanate (Compound No. 11)
- 26 (S)-N-[1-[[3-[3-Fluoro-4-[N-1-[4-{2-thienyl-(5-nitro)methyl}] piperazinyl]
27 phenyl]-2-oxo-5-oxazolidinyl]methyl]]-thiourea (Compound No. 12)
- 28 (S)-N-[[3-[3-Fluoro-4-[N-1-[4-{2-furyl-(5-nitro)methyl}] piperazinyl] phenyl]-2-
29 oxo-5-oxazolidinyl]methyl]isothiocyanate (Compound No. 13)
- 30 5(S)-Isoxazol-3-yl-oxymethyl-3-[3-fluoro-4-[4-[(4-bromo-5-nitro-2-thienyl)
31 methyl]piperazinyl-1-yl]phenyl]oxazolidin-2-one (Compound No. 14)
- 32 5(S)-Isoxazol-3-yl-oxymethyl-3-[3-fluoro-4-[4-[(5-nitro-2-furyl)methyl]
33 piperazinyl-1-yl]phenyl]oxazolidin-2-one (Compound No. 15)
- 34 5(S)-Isoxazol-3-yl-oxymethyl-3-[3-fluoro-4-[4-[(5-nitro-2-thienyl)
35 methyl]piperazinyl-1-yl]phenyl]oxazolidin-2-one (Compound No. 16)

36 (S)-N-[1-[[3-[3-Fluoro-4-[N-1-[4-{2-furyl-(5-nitro)methyl}] piperazinyl] phenyl]-
37 2-oxo-5-oxazolidinyl]methyl]]3,3-dimethyl-thiourea (Compound No. 17)

38 (S)-N-[3-[3-Fluoro-4-[N-1-[4-{2-thienyl-(5-nitro)methyl}] piperazinyl]
39 phenyl]-2-oxo-5-oxazolidinyl]methylamine (Compound No. 18)

1 10. (Original) A pharmaceutical composition comprising the compound of claims
2 1, 2 or 9 and a pharmaceutical acceptable carrier.


1 11. (Original) A pharmaceutical composition comprising a pharmaceutically
2 effective amount of compound according to claims 1, 2 or 9 or a physiologically
3 acceptable acid addition salt thereof with a pharmaceutical acceptable carrier for treating
4 microbial infections.

1 12. (Original) A method of treating or preventing microbial infections in a
2 mammal comprising administering to the said mammal, the pharmaceutical composition
3 according to claim 11.

1 13. (Original) The method according to claim 12 wherein the microbial infections
2 are caused by gram-positive and gram-negative bacteria.

1 14. (Cancelled).

1 15. (Original) A method of treating or preventing aerobic and anaerobic bacterial
2 infections in a mammal comprising administering to said mammal, a therapeutically
3 effective amount of a compound having the structure of Formula I




7 **Formula I**

8 and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters,
9 enantiomers, diastereomers, N-oxides, polymorphs, prodrugs or metabolites, wherein

- 10 T is a five to seven membered heterocyclic ring, substituted heterocyclic ring, aryl or
 11 substituted aryl, bound to the ring C with a linker W, and is further substituted by a group
 12 represented by R, wherein R is H, C₁₋₆ alkyl, F, Cl, Br, I, -CN, COR₅, COOR₅, N(R₆,R₇),
 13 NHCOC(R₈, R₉, R₁₀), CON(R₆, R₇), CH₂NO₂, NO₂, CH₂R₈, CHR₉, -CH = N-OR₁₀, -
 14 C=CH-R₅, OR₅, SR₅, -C(R₉)=C(R₉)NO₂, C₁₋₁₂ alkyl substituted with one or more of F, Cl,
 15 Br, I, OR₄, SR₄, wherein R₄ is hydrogen, alkoxy, aryl, heteroaryl, amines, substituted
 16 amines, alkene substituted with aryl, heteroaryl or halogens; R₅ is H, C₁₋₁₂ alkyl, C₃₋₁₂
 17 cycloalkyl, C₁₋₆ alkoxy, aryl or heteroaryl; C₁₋₆ alkyl substituted with one or more of F,
 18 Cl, Br, I or OH;
- 19 R₆ and R₇ are independently H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆
 20 alkoxy;
- 21 R₈ and R₉ are independently H, C₁₋₆ alkyl, F, Cl, Br, I, C₁₋₁₂ alkyl substituted with one or
 22 more of F, Cl, Br, I, OR₅, SR₄, or N(R₆,R₇);
- 23 R₁₀= H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, aryl or
 24 heteroaryl;
- 25 n is an integer in the range from 0 to 3;
- 26 X is H, CH, CH-S, CH-O, N, CHNR₁₁ or CCH₂NR₁₁, wherein R₁₁ is hydrogen, optionally
 27 substituted C₁₋₁₂ alkyl C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkylcarbonyl, C₁₋₆
 28 alkylcarboxy, aryl or heteroaryl;
- 29 Y and Z are independently hydrogen, C₁₋₆ alkyl, C₃₋₁₂ cycloalkyl, C₀₋₃ bridging groups;
- 30 U and V are independently hydrogen, optionally substituted C₁₋₆ alkyl, F, Cl, Br, I, C₁₋₁₂
 31 alkyl substituted with one or more of F, Cl, Br, I;
- 32 W is CH₂, CO, CH₂NH, -NHCH₂, -CH₂NHCH₂, -CH₂-N (R₁₁)CH₂-, CH₂(R₁₁)N-,
 33 CH(R₁₁), S, CH₂(CO), NH, O, NR₁₁, (CO)CH₂, N(R₁₁)CON(R₁₁), N(R₁₁)C(=S)N(R₁₁),
 34 SO₂ or SO; wherein R₁₁ is hydrogen, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl,
 35 C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkylcarbonyl, C₁₋₆ alkylcarboxy, aryl or heteroaryl; and

36 R_1 is $\text{NHC}(=\text{O})R_2$, $\text{NHC}(=\text{S})R_2$, $\text{N}(R_3, R_4)$, NR_3 or OR_3 , wherein R_2 , R_3 , R_4 are
 37 independently hydrogen, thiocarbonyl, amines, substituted amines, aryl heteroaroyl,
 38 heterocyclic, aralkyl, aralkenyl, wherein the heteroaroyl and heterocyclic rings may contain
 39 one or more heteroatoms selected from O, S and N; the aryl, heteroaroyl, aralkyl and
 40 aralkenyl rings may be unsubstituted or substituted with one or more of alkyl, halogen,
 41 nitro, amino or methylenedioxy.

1 16. (Original) A method of treating or preventing aerobic and anaerobic bacterial
 2 infections in a mammal comprising administering to said mammal, a therapeutically
 3 effective amount of a compound having the structure of Formula II:



7 **Formula II**

8 and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters,
 9 enantiomers, diastereomers, N-oxides, polymorphs, prodrugs or metabolites, wherein

10 R_1 is $\text{NHC}(=\text{O})R_2$, $\text{NHC}(=\text{S})R_2$, $\text{N}(R_3, R_4)$, NR_3 or OR_3 , wherein R_2 , R_3 , R_4 are
 11 independently hydrogen, thiocarbonyl, amines, substituted amines, aryl heteroaroyl,
 12 heterocyclic, aralkyl, aralkenyl, wherein the heteroaroyl and heterocyclic rings may contain
 13 one or more of heteroatoms selected from O, S and N; the aryl, heteroaroyl, aralkyl and
 14 aralkenyl rings may be unsubstituted or substituted with one or more of alkyl, halogen,
 15 nitro, amino or methylenedioxy;

16 U and V are independently hydrogen, optionally substituted C_{1-6} alkyl, F, Cl, Br, I, C_{1-12}
 17 alkyl substituted with one or more of F, Cl, Br, I;

18 Y and Z are independently hydrogen, C_{1-6} alkyl, C_{3-12} cycloalkyl, C_{0-3} bridging group;

19 X is H, CH, CH-S, CH-O, N, CHNR_{11} or $\text{CCH}_2\text{NR}_{11}$, wherein R_{11} is hydrogen, optionally
 20 substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl carbonyl, C_{1-6}
 21 alkylcarboxy, aryl or heteroaroyl;

22 **W** is CH₂, C=O, CH₂NH, NHCH₂, CH₂NHCH₂, CH₂N(R₁₁)CH₂, CH₂N(R₁₁),
 23 CH(R₁₁), S, CH₂(C=O), NH, O, (CO)CH₂, N(R₁₁)CON(R₁₁), SO₂, SO, NR₁₁,
 24 N(R₁₁)C(=S)N(R₁₁); wherein R₁₁ is hydrogen, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂
 25 cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl carbonyl, C₁₋₆ alkylcarboxy, aryl or heteroaryl;

26 **n** is an integer in the range from 0 to 3;

27 **Q₁** is O, S or NR₁₁, wherein R₁₁ is as defined earlier;

28 **G, J, L** are independently H, C₁₋₆ alkyl, F, Cl, Br, I, -CN, COR₅, COOR₅, N(R₆,R₇),
 29 NHCOC(R₈, R₉, R₁₀), CON(R₆, R₇), CH₂NO₂, NO₂, CH₂R₈, CHR₉, -CH = N-OR₁₀, -
 30 C=CH-R₅, OR₅, SR₅, -C(R₉)=C(R₉)NO₂, C₁₋₁₂ alkyl substituted with one or more F, Cl,
 31 Br, I, OR₄, SR₄, wherein R₄ is as defined above; R₅ is H, C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆
 32 alkoxy, aryl or heteroaryl; C₁₋₆ alkyl substituted with one or more of F, Cl, Br, I or OH;


33 R₆ and R₇ are independently H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl or C₁₋₆
 34 alkoxy;

35 R₈ and R₉ are independently H, C₁₋₆ alkyl, F, Cl, Br, I, C₁₋₁₂ alkyl substituted with one or
 36 more of F, Cl, Br, I, OR₅, SR₄, N(R₆,R₇); and

37 R₁₀= H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, aryl or
 38 heteroaryl.

1 17. - 19. (Cancelled)


2 20. (Original) The method according to claim 16 having the structure of Formula
 3 **III**,



7 **FORMULA III**

8 wherein U, V, Y, Z, W, X, G, J, L, R₁, R₁₁ and n are as defined earlier.


21. (Original) The method according to claim 16 having the structure of Formula IV,



FORMULA IV

wherein U, V, Y, Z, W, X, G, J, L, R₁ and n are as defined earlier.


22. (Original) The method according to claim 16 having the structure of Formula V,



FORMULA V

wherein U, V, X, Y, Z, W, G, J, L, R₁ and n are as defined earlier.

23. (Original) A process for preparing a compound of Formula I,




Formula I

and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, prodrugs or metabolites, wherein

- 1 **T** is a five to seven membered heterocyclic ring, substituted heterocyclic ring, aryl or
 2 substituted aryl, bound to the ring **C** with a linker **W**, and is further substituted by a group
 3 represented by **R**, wherein **R** is H, C₁₋₆ alkyl, F, Cl, Br, I, -CN, COR₅, COOR₅, N(R₆,R₇),
 4 NHCO(R₈, R₉, R₁₀), CON(R₆, R₇), CH₂NO₂, NO₂, CH₂R₈, CHR₉, -CH = N-OR₁₀, -C=CH-
 5 R₅, OR₅, SR₅, -C(R₉)=C(R₉)NO₂, C₁₋₁₂ alkyl substituted with one or more of F, Cl, Br, I, OR₄,
 6 SR₄, wherein R₄ is hydrogen, alkoxy, aryl, heteroaryl, amines, substituted amines, alkene
 7 substituted with aryl, heteroaryl or halogens; R₅ is H, C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy,
 8 aryl or heteroaryl; C₁₋₆ alkyl substituted with one or more of F, Cl, Br, I or OH;
- 9 R₆ and R₇ are independently H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆
 10 alkoxy;
- 11 R₈ and R₉ are independently H, C₁₋₆ alkyl, F, Cl, Br, I, C₁₋₁₂ alkyl substituted with one or more
 12 of F, Cl, Br, I, OR₅, SR₄, or N(R₆,R₇);
- 13 R₁₀= H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, aryl or
 14 heteroaryl;
- 15 **n** is an integer in the range from 0 to 3;
- 16 **X** is H, CH, CH-S, CH-O, N, CHNR₁₁ or CCH₂NR₁₁, wherein R₁₁ is hydrogen, optionally
 17 substituted C₁₋₁₂ alkyl C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkylcarbonyl, C₁₋₆
 18 alkylcarboxy, aryl or heteroaryl;
- 19 **Y** and **Z** are independently hydrogen, C₁₋₆ alkyl, C₃₋₁₂ cycloalkyl, C₀₋₃ bridging groups;
- 20 **U** and **V** are independently hydrogen, optionally substituted C₁₋₆ alkyl, F, Cl, Br, I, C₁₋₁₂ alkyl
 21 substituted with one or more of F, Cl, Br, I;
- 22 **W** is CH₂, CO, CH₂NH, -NHCH₂, -CH₂NHCH₂, -CH₂-N (R₁₁)CH₂-, CH₂(R₁₁)N-, CH(R₁₁), S,
 23 CH₂(CO), NH, O, NR₁₁, (CO)CH₂, N(R₁₁)CON(R₁₁), N(R₁₁)C(=S)N(R₁₁), SO₂ or SO;
 24 wherein R₁₁ is hydrogen, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆
 25 alkyl, C₁₋₆ alkylcarbonyl, C₁₋₆ alkylcarboxy, aryl or heteroaryl; and

R_1 is $NHC(=O)R_2$, $NHC(=S)R_2$, $N(R_3, R_4)$, NR_3 or OR_3 , wherein R_2 , R_3 , R_4 are independently hydrogen, thiocarbonyl, amines, substituted amines, aryl heteroaroyl, heterocyclic, aralkyl, aralkenyl, wherein the heteroaryl and heterocyclic rings may contain one or more heteroatoms selected from O, S and N; the aryl, heteroaryl, aralkyl and aralkenyl rings may be unsubstituted or substituted with one or more of alkyl, halogen, nitro, amino or methylenedioxy;

which comprises reacting an amine of Formula VI,




Formula VI

with a heteroaromatic compound of Formula R-T-W- R_{12} wherein R, T, W, R_1 , Y, Z, U, V and n are as defined earlier and M_1 is NH, NHR_{13} , $CHNHR_{13}$, $-CHCH_2NHR_{13}$, $-CCH_2NHR_{13}$, wherein R_{13} is H, ethyl, methyl, isopropyl, acetyl, cyclopropyl, alkoxy or acetyl and R_{12} is a suitable leaving group selected from the group consisting of fluoro, chloro, bromo, iodo, SCH_3 , $-SO_2CH_3$, $-SO_2CF_3$, Tos, OC_6H_5 , $-COOH$ or $-CHO$.

24. (Cancelled).

25. (Original) A process for preparing a compound of Formula II,



Formula II


and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, prodrugs or metabolites, wherein

- 1 R_1 is $NHC(=O)R_2$, $NHC(=S)R_2$, $N(R_3, R_4)$, NR_3 or OR_3 , wherein R_2 , R_3 , R_4 are independently
2 hydrogen, thiocarbonyl, amines, substituted amines, aryl heteroaroyl, heterocyclic, aralkyl,
3 aralkenyl, wherein the heteroaroyl and heterocyclic rings may contain one or more of
4 heteroatoms selected from O, S and N; the aryl, heteroaroyl, aralkyl and aralkenyl rings may be
5 unsubstituted or substituted with one or more of alkyl, halogen, nitro, amino or
6 methylenedioxy;
- 7 U and V are independently hydrogen, optionally substituted C_{1-6} alkyl, F, Cl, Br, I, C_{1-12} alkyl
8 substituted with one or more F, Cl, Br, I;
- 9 Y and Z are independently hydrogen, C_{1-6} alkyl, C_{3-12} cycloalkyl, C_{0-3} bridging group;
- 10 X is H, CH, CH-S, CH-O, N, $CHNR_{11}$ or CCH_2NR_{11} , wherein R_{11} is hydrogen, optionally
11 substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl carbonyl, C_{1-6} alkylcarboxy,
12 aryl or heteroaroyl;
- 13 W is CH_2 , $C=O$, CH_2NH , $NHCH_2$, CH_2NHCH_2 , $CH_2N(R_{11})CH_2$, $CH_2N(R_{11})$, $CH(R_{11})$, S,
14 $CH_2(C=O)$, NH, O, $(CO)CH_2$, $N(R_{11})CON(R_{11})$, SO_2 , SO, NR_{11} , $N(R_{11})C(=S)N(R_{11})$;
15 wherein R_{11} is hydrogen, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6}
16 alkyl carbonyl, C_{1-6} alkylcarboxy, aryl or heteroaroyl;
- 17 n is an integer in the range from 0 to 3;
- 18 Q_1 is O, S or NR_{11} , wherein R_{11} is as defined earlier;
- 19 G , J , L are independently H, C_{1-6} alkyl, F, Cl, Br, I, $-CN$, COR_5 , $COOR_5$, $N(R_6, R_7)$,
20 $NHCOC(R_8, R_9, R_{10})$, $CON(R_6, R_7)$, CH_2NO_2 , NO_2 , CH_2R_8 , CHR_9 , $-CH = N-OR_{10}$, $-C=CH-$
21 R_5 , OR_5 , SR_5 , $-C(R_9)=C(R_9)NO_2$, C_{1-12} alkyl substituted with one or more F, Cl, Br, I, OR_4 ,
22 SR_4 , wherein R_4 is as defined above; R_5 is H, C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, aryl or
23 heteroaroyl; C_{1-6} alkyl substituted with one or more of F, Cl, Br, I or OH;
- 24 R_6 and R_7 are independently H, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl or C_{1-6}
25 alkoxy;


1 R_8 and R_9 are independently H, C_{1-6} alkyl, F, Cl, Br, I, C_{1-12} alkyl substituted with one or more
 2 of F, Cl, Br, I, OR_5 , SR_4 , $N(R_6, R_7)$; and

3 R_{10} = H, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl or
 4 heteroaryl;

5 comprising reacting a compound of Formula VI,



9 with a heteroaromatic compound of Formula VII,



13 wherein R_1 , U, V, Y, Z, G, J, L and Q_1 are as defined earlier and M_1 is NH, NHR_{13} ,
 14 $CHNHR_{13}$, $-CHCH_2NHR_{13}$, $-CCH_2NHR_{13}$, wherein R_{13} is H, ethyl, methyl, isopropyl, acetyl,
 15 cyclopropyl, alkoxy or acetyl and R_{12} is a suitable leaving group selected from the group
 16 consisting of fluoro, chloro, bromo, iodo, SCH_3 , $-SO_2CH_3$, $-SO_2CF_3$, Tos, OC_6H_5 , $-COOH$ or
 17 $-CHO$.

1 26.-41. (Cancelled)